The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Open accessAbstract
OBJECTIVE: This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma. METHODS: The European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) CE.3 clinical trial database of radiotherapy (RT) with or without temozolomide (TMZ) for newly diagnosed glioblastoma was examined to assess the impact of the interaction between AED use and chemoradiotherapy on survival. Data were adjusted for known prognostic factors. RESULTS: When treatment began, 175 patients (30.5%) were AED-free, 277 (48.3%) were taking any enzyme-inducing AED (EIAED) and 135 (23.4%) were taking any non-EIAED. Patients receiving valproic acid (VPA) only had more grade 3/4 thrombopenia and leukopenia than patients without an AED or patients taking an EIAED only. The overall survival (OS) of patients who were receiving an AED at baseline vs not receiving any AED was similar. Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93). CONCLUSIONS: VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationEpilepsy in patients with brain tumours: epidemiology, mechanisms, and management
van Breemen, M. S., Wilms, E. B., & Vecht, C. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70103-5 · Cited by 913
Self-citationGlantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Self-citationThe Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors
Eyal, S., Yagen, B., Sobol, E., Altschuler, Y., Shmuel, M., & Bialer, M. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.00104.x · Cited by 205
Li, X.-N., Shu, Q., Su, J. M.-F., Perlaky, L., Blaney, S. M., & Lau, C. C. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0184 · Cited by 201
Oberndorfer, S., Piribauer, M., Marosi, C., Lahrmann, H., Hitzenberger, P., & Grisold, W. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-2338-2 · Cited by 183
Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines
Fu, J., Shao, C.-J., Chen, F.-R., Ng, H.-K., & Chen, Z.-P. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop005 · Cited by 164
Münster, P. N., Marchion, D. C., Biçaku, E., Lacevic, M., Kim, J., Centeno, B. A., DAUD, A. I., Neuger, A. M., Minton, S. E., & Sullivan, D. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1930 · Cited by 150
Cited by
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Molecular targeted therapy of glioblastoma
Le Rhun, E., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M., Wen, P., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 688
Self-citationPaediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
Metadata
- Authors
- Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., Rossetti, A. O., Lacombe, D., Mirimanoff, R.-O., Vecht, C. J., & Stupp, R.
- Venue
- Neurology
- Published
- 2011-09-20
- Volume
- 77
- Issue
- 12
- Pages
- 1156-1164
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2091956563
- Cited by
- 290
- References
- 18
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. https://app.cochat.ai/papers/10.1212/wnl.0b013e31822f02e1
- The paper
- Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., Rossetti, A. O., Lacombe, D., Mirimanoff, R.-O., Vecht, C. J., & Stupp, R. (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. https://doi.org/10.1212/wnl.0b013e31822f02e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.